Compare VLN & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | FATE |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | Israel | United States |
| Employees | 233 | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.9M | 125.6M |
| IPO Year | N/A | 2013 |
| Metric | VLN | FATE |
|---|---|---|
| Price | $3.06 | $2.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $4.10 |
| AVG Volume (30 Days) | ★ 4.8M | 3.3M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $8.37 | N/A |
| Revenue Next Year | $16.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $0.91 |
| 52 Week High | $3.50 | $2.47 |
| Indicator | VLN | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 59.77 |
| Support Level | $1.48 | $1.00 |
| Resistance Level | $3.50 | N/A |
| Average True Range (ATR) | 0.32 | 0.27 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 68.53 | 58.29 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.